Comparison of Plasma active glucagon-like peptide-1 (GLP-1) levels assayed with or without plasma extraction in non-diabetic men

Endocrine Journal

Volumn 59, Issue 5, 2012, Pages 435-438

  Masuda, Kiyomi ^a   Aoki, Kazutaka ^a   Terauchi, Yasuo ^a  

^a YOKOHAMA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Active glucagon like peptide 1; Extraction

Indexed keywords

ALCOHOL; GLUCAGON LIKE PEPTIDE 1;

ACCURACY; ADULT; CLINICAL ARTICLE; CONTROLLED STUDY; CROSS REACTION; EXTRACTION; HUMAN; INTERMETHOD COMPARISON; JAPAN; MALE; MEDICAL SOCIETY; NOTE; PROTEIN BLOOD LEVEL; SOLID PHASE EXTRACTION;

ADULT; ANALYTIC SAMPLE PREPARATION METHODS; ENZYME-LINKED IMMUNOSORBENT ASSAY; ETHANOL; GLUCAGON-LIKE PEPTIDE 1; GUIDELINES AS TOPIC; HUMANS; MALE; MIDDLE AGED; REPRODUCIBILITY OF RESULTS; SOLID PHASE EXTRACTION; SOLVENTS;

EID: 84861877594     PISSN: 09188959     EISSN: 13484540     Source Type: Journal    
DOI: 10.1507/endocrj.EJ12-0009     Document Type: Note

References (16)

1. Baggio LL, Drucker DJ (2007) Biology of incretins: GLP-1 and GIP. Gastroenterology 132: 2131-2157.
2. Holst JJ (2007) The physiology of glucagon-like pep-tide 1. Physiological Reviews 87: 1409-1439.
3. Herman GA, Bergman A, Stevens C, Kotey P, Yi B, et al. (2006) Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes. J Clin Endocrinol Metab 91: 4612-4619.
4. Seino Y, Fukushima M, Yabe D (2010) GIP and GLP-1, the two incretin hormones: similarities and differences. J Diabetes Invest 1: 9-23.
5. Vilsbøll T, Krarup T, Sonne J, Madsbad S, Vølund A, et al. (2003) Incretin secretion in relation to meal size and body weight in healthy subjects and people with type 1 and type 2 diabetes mellitus. J Clin Endocrinol Metab 88: 2706-2713.
6. Meier JJ, Nauck MA, Kranz D, Holst JJ, Deacon CF, et al. (2004) Secretion, degradation, and elimination of glucagon-like peptide 1 and gastric inhibitory poly-peptide in patients with chronic renal insuffciency and healthy control subjects. Diabetes 53: 654-662.
7. Deacon CF, Holst JJ (2009) Immunoassays for the incretin hormones GIP and GLP-1. Best Pract Res Clin Endocrinol Metab 23: 425-432.
8. http://www.jds.or.jp/jds_or_jp0/uploads/photos/786.pdf
9. Masuda K, Aoki K, Terauchi Y (2011) Effects of migli-tol taken just before or after breakfast on plasma glucose, serum insulin, glucagon and incretin levels after lunch in men with normal glucose tolerance (NGT), impaired fasting glucose (IFG) or impaired glucose tolerance (IGT). J Diabates Invest 2: 435-440.
10. Seino Y, Nanjo K, Tajima N, Kadowaki T, Kashiwagi A, et al. (2010) Report of the Committee on the Classifcation and Diagnostic Criteria of Diabetes Mellitus. J Diabetes Invest 1: 212-228.
11. Seino Y, Nanjo K, Tajima N, Kadowaki T, Kashiwagi A, et al. (2010) Report of the Committee on the Classifcation and Diagnostic Criteria of Diabetes Mellitus. Diabetol Int 1: 2-20.
12. Glucagon-Like Peptide-1 (Active) ELISA Kit 96-Well Plate (Cat. # EGLP-35K). Copyright 2008 Millipore Corporation, Billerica, MA, U.S.A
13. Yabe D, Watanabe K, Sugawara K, Kuwata H, Kitamoto Y, et al. (2012) Comparison of incretin immunoassays with or without plasma extraction: Incretin secretion in Japanese patients with type 2 diabetes. J Diabates Invest 3: 70-79.
14. Yabe D, Kuroe A, Lee S, Watanabe K, Hyo T, et al. (2010) Little enhancement of meal-induced glucagons-like peptide 1 secretion in Japanese: Comparison of type 2 diabetes patients and healthy controls. J Diabates Invest 1: 56-59.
15. Dai H, Gustavson SM, Preston GM, Eskra JD, Calle R, et al. (2008) Non-linear increase in GLP-1 levels in response to DPP-IV inhibition in healthy adult subjects. Diabetes Obes Metab 10: 506-513.
16. LaMarca CJ, Perregaux DG, Preston GM, Shaw CM, Gao P (2009) Comparison and validation of multiple commercially available methods for active GLP-1 quan-tifcation: sample extraction is a ubiquitous requirement. In: ENDO 2009. Washington, D.C.